DIEBOLD NIXDORF INC (DBD) is down -17.17% in the latest session. Our newswire has captured 5 stories on DBD across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
DBD stock fell 17.17% to $75.17 on Tuesday, marking one of the largest declines in its 52-week range of $53.93 to $92.08. The drop came after the company reported Q2 2026 earnings and reaffirmed its full-year guidance, despite beating revenue estimates and reporting in-line non-GAAP EPS. The move suggests a shift in investor sentiment following the earnings call, where management outlined challenges including memory cost headwinds and inventory build, which may have raised concerns about near-term profitability.
Diebold Nixdorf reported Q2 2026 non-GAAP EPS of $1.10, in line with expectations, and revenue of $927.6 million, which beat estimates by $1.37 million. The company reaffirmed its 2026 adjusted EBITDA guidance of $510 million to $535 million and free cash flow guidance of $255 million to $270 million. Despite these positive metrics, the earnings call highlighted potential headwinds, including rising memory costs and inventory management challenges. These factors, combined with a Q4 cash flow outlook that may not meet expectations, appear to have triggered the sharp sell-off.
The stock’s decline occurred amid a trading session that saw significant volume, though specific figures were not provided. Over the past 90 days, insiders have executed 5 sell transactions totaling $50.0 million, with Millstreet Capital Management LLC selling shares on three separate occasions in June 2026. The company’s fundamentals show a market cap of $3.1 billion, a P/E ratio of 30.9, and trailing 12-month revenue growth of 4.3%. However, its net margin of 2.8% and beta of 1.11 suggest relatively modest profitability and above-average volatility compared to the market.
With the Q2 2026 earnings behind it, investors will now look to the company’s performance in the coming quarters to see if it can navigate the outlined challenges. The next earnings report is scheduled for April 30, 2026, and coverage breadth will remain a key metric to monitor as the stock continues to trade near its 52-week low.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Diebold Nixdorf (DBD) Q2 2026 earnings call: revenue, EPS and reaffirmed guidance, plus memory cost headwinds, inventory build and Q4 cash flow drivers—read...
Diebold Nixdorf, Incorporated (DBD) Q2 2026 Earnings Call July 29, 2026 8:30 AM EDTCompany ParticipantsMaynard Um - Vice President of Investor...
Diebold Nixdorf (DBD) Q2 results: Non-GAAP EPS $1.10 in-line, revenue $927.6M beat, and FY2026 outlook reaffirmed.
Filed: 2026-07-29 AccNo: 0000028823-26-000031 Size: 1 MB Item 2.02: Results of Operations and Financial Condition
Revenue grew more than 1% and order entry increased 3% YoY Net income grew 28% YoY, with net income margin expanding 30 bps YoY Adjusted EBITDA grew 8% YoY, and adjusted EBITDA margin expanded by 80 bps YoY Earnings per share grew 33% on a GAAP basis YoY, and grew 17% on a non-GAAP basis...
DIEBOLD NIXDORF INC (DBD) is down -17.17% in the latest session. Our newswire has captured 5 stories on DBD across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100). The most recent driver: "Diebold nixdorf reaffirms 2026 adjusted EBITDA of $510M-$535M while targeting $255M-$270M in free cash flow" (Seeking Alpha).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of DBD coverage reads 55/100 over 5 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on DBD: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier DBD move explainers: 2026-07-30 · 2026-07-29